Product Description
Palonosetron injection is used to prevent nausea and vomiting that may occur within 24 hours after receiving cancer chemotherapy or surgery. It is also used to prevent delayed nausea and vomiting that may occur several days after receiving certain chemotherapy medications. Palonosetron injection is in a class of medications called 5-HT3 receptor antagonists.
Mechanisms of Action: 5-HT3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Oncology Unspecified
Known Adverse Events: Headache | Constipation
Company: Helsinn Healthcare
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Nose Cancer
Phase 2: Breast Cancer|Central Nervous System Cancer|Cervical Cancer|Lymphoma|Motion Sickness|Other|Pregnancy Outcomes
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SWC999 | P2 |
Recruiting |
Pregnancy Outcomes|Motion Sickness|Central Nervous System Cancer |
2023-12-31 |
|
| CTR20221765 | P1 |
Completed |
Healthy Volunteers |
2022-12-07 |
|
| NCI-2017-00599 | P3 |
Completed |
Nose Cancer |
2022-02-14 |
|
| 2020-003730-20 | P2 |
Active, not recruiting |
Nose Cancer |
2021-05-07 |